title: CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.
authors.affiliation: Department of Pharmacotherapy, Meiji Pharmaceutical University, Tokyo, Japan. harumit@my-pharm.ac.jp
authors.forename: Harumi
authors.initials: H
authors.lastname: Takahashi
authors.forename: Grant R
authors.initials: GR
authors.lastname: Wilkinson
authors.forename: Roberto
authors.initials: R
authors.lastname: Padrini
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Echizen
mesh_terms: D000074:Acenocoumarol / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D006801:Humans; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D014859:Warfarin / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D000925:Anticoagulants; D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D000074:Acenocoumarol